XTL Biopharmaceuticals
XTLB
3 hedge funds and large institutions have $240K invested in XTL Biopharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
50% more funds holding
Funds holding: 2 → 3 (+1)
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
24% less capital invested
Capital invested by funds: $316K → $240K (-$75.4K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$245 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$734 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NI
1
Noked Israel
Ramat Hasharon,
Israel
| $199K | – | – | – |
|
|
2
Morgan Stanley
New York
| $41.2K | -$734 | -150 | -1% |
|
|
3
BNP Paribas Financial Markets
Paris,
France
| $200 | +$245 | +50 | New |
|
XTLB Hedge Fund Activity: Q2 2023 in Review
3 of the 6,372 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q2 2023, worth a combined $240K — down 24% from $316K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new XTLB positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was BNP Paribas Financial Markets, opening a new position worth an estimated $245. The largest seller was Morgan Stanley, cutting an estimated $734.
- 3 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q2 2023, up from 2 in Q1 2023.
- Funds reported $240K of XTL Biopharmaceuticals stock for Q2 2023, down 24% quarter-over-quarter.
- 1 fund opened new XTL Biopharmaceuticals positions in Q2 2023 and 0 closed out, a net change of +1 holder.
- The largest XTL Biopharmaceuticals buyer in Q2 2023 was BNP Paribas Financial Markets, an estimated $245 added.
- The largest XTL Biopharmaceuticals seller in Q2 2023 was Morgan Stanley, an estimated $734 sold.
Based on aggregated 13F filings for Q2 2023.